Namyang Dairy is in trouble after a number of furious investors have called for a boycott. They urged the consumers to stop buying the company’s products.
Namyang’s COVID-19 claim
The root cause of this action from the investors was Namyang Dairy’s claim that its Bulgaris yogurt drink can help fight the symptoms of COVID-19. Last week, the South Korean food and dairy company said that its stock price increased by more than eight percent on April 13 and continued to go up to over 28% the next day.
At that time, it was reported that Namyang’s share surge was caused by the consumers’ rush to buy its Bulgaris yogurt after it released a statement saying that the product can prevent COVID-19. However, health officials are questioning the company’s claims and suggested that they are false and have no scientific basis.
The controversial claim was announced during a symposium hosted by the Korea Research & Institute of BioMedical last week. At the event, Namyang’s internal research institute presented the results of its research on Yogurt drink called Bulgaris, as per The Korea Herald.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Company’s representative, Park Jong Su, said at the symposium. “Our experiments showed that Bulgaris helped remove the influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
S. Korea’s food and drug ministry reacts
The experts from the Ministry of Food and Drug Safety and Korea Disease Control and Prevention Agency immediately questioned Namyang’s statements about its Bulgaris yogurt. They are asking about the effectiveness claim against COVID-19 and they concluded that the dairy firm exaggerated the research results that it released in the previous symposium.
The Korea Times reported that because of this, the investors are now taking action against Namyang. They are using social media to ask the public to join in their calls to boycott the company’s products. Apparently, they are angry not just due to the coronavirus statements but also because they believe Namyang lied to manipulate the stock price.
Meanwhile, amid the backlash from the public and health experts, Namyang Dairy issued an apology for the confusion. "We apologize to our customers for causing misunderstanding with our research results,” a company official stated. “The test was not based on human testing, but at the cellular stage, from which we couldn't have concluded its effectiveness against COVID-19."


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 



